Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of “Moderate Buy” by Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $14.25.

OBIO has been the topic of a number of research reports. Wall Street Zen upgraded shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Barclays raised their price target on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. TD Cowen assumed coverage on shares of Orchestra BioMed in a research note on Wednesday, December 10th. They issued a “buy” rating for the company. Finally, Chardan Capital reiterated a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th.

Insider Buying and Selling

In other news, insider David P. Hochman purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the purchase, the insider owned 1,086,467 shares in the company, valued at $4,660,943.43. This represents a 0.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Orchestra BioMed

Several hedge funds and other institutional investors have recently modified their holdings of OBIO. Vanguard Group Inc. raised its position in shares of Orchestra BioMed by 28.0% during the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after purchasing an additional 324,558 shares during the period. Alyeska Investment Group L.P. acquired a new stake in Orchestra BioMed in the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC bought a new stake in Orchestra BioMed during the 3rd quarter valued at $2,495,000. Geode Capital Management LLC increased its stake in Orchestra BioMed by 22.4% during the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock valued at $1,965,000 after purchasing an additional 86,564 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Orchestra BioMed by 46.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock worth $1,095,000 after buying an additional 83,349 shares during the last quarter. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Trading Down 1.9%

NASDAQ OBIO opened at $4.57 on Thursday. The stock has a market capitalization of $267.44 million, a P/E ratio of -4.04 and a beta of 0.56. The business has a 50 day simple moving average of $4.20 and a 200 day simple moving average of $3.95. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.45 and a quick ratio of 6.43. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.64. The firm had revenue of $30.92 million for the quarter, compared to analyst estimates of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%. Research analysts expect that Orchestra BioMed will post -1.66 earnings per share for the current year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.